Neurocrine Biosciences Stock (NASDAQ:NBIX)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$125.74

52W Range

$106.85 - $157.98

50D Avg

$118.43

200D Avg

$134.24

Market Cap

$12.88B

Avg Vol (3M)

$957.74K

Beta

0.35

Div Yield

-

NBIX Company Profile


Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1,700

IPO Date

May 23, 1996

Website

NBIX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Product$1.86B$1.44B$1.09B
Collaboration Revenue$26.50M$47.80M$43.40M

Fiscal year ends in Dec 23 | Currency in USD

NBIX Financial Summary


Dec 23Dec 22Dec 21
Revenue$1.89B$1.49B$1.13B
Operating Income$250.90M$249.00M$196.90M
Net Income$249.70M$154.50M$89.60M
EBITDA$250.90M$249.00M$207.80M
Basic EPS$2.56$1.61$0.95
Diluted EPS$2.47$1.56$0.92

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 30, 24 | 3:11 PM
Q2 24Aug 01, 24 | 3:24 PM
Q1 24May 01, 24 | 12:00 AM

Peer Comparison


TickerCompany
SUPNSupernus Pharmaceuticals, Inc.
ITCIIntra-Cellular Therapies, Inc.
ANIPANI Pharmaceuticals, Inc.
DVAXDynavax Technologies Corporation
IRWDIronwood Pharmaceuticals, Inc.
DCPHDeciphera Pharmaceuticals, Inc.
PBHPrestige Consumer Healthcare Inc.
ALKSAlkermes plc
PCRXPacira BioSciences, Inc.
EVOEvotec SE
COLLCollegium Pharmaceutical, Inc.
AVDLAvadel Pharmaceuticals plc
EGRXEagle Pharmaceuticals, Inc.
AMPHAmphastar Pharmaceuticals, Inc.